Ambu A/S: Changes within the board of directors of Ambu A/S

Ambu A/S announces today that the chairman of the board of directors Jens Bager has informed the board of directors that after 9 years of service he wishes to resign from the board of directors. Jens Bager will resign as of Ambu’s annual general meeting in December 2019.Ambu’s board of directors proposes that Lars Rasmussen is elected as new chairman of the board of directors at the annual general meeting. Lars Rasmussen is, among others, chairman of the board of directors of Coloplast A/S and H. Lundbeck A/S.Furthermore, the board of directors proposes that Britt Meelby Jensen, CEO of the Swedish medtech company Atos Medical AB, is elected as new member of the board of directors at Ambu’s annual general meeting.Commenting on his decision Jens Bager says:It is with pride that I now leave Ambu. During the years of my tenure as chairman of the board of directors, the company has multiplied its turnover as well as value and recently we have been successful in recruiting Juan Jose Gonzalez as new CEO. The company now faces a new journey that can make Ambu one of the top players within visualization.Because of that, I have found this moment ideal to make room for new capabilities in the chairmanship which along with the remaining board members and management board can take Ambu to the next level.I would also take the opportunity to thank my colleagues in the management board, the board of directors, Ambu’s shareholders and the company’s employees for having been able to act as chairman of the board of directors during a period in which the development of Ambu has been exceptionally positive.Lars Rasmussen was born in 1959 and has vast experience within the medtech industry through a long career in Coloplast A/S in which he acted as CEO for 10 years. Lars Rasmussen is today chairman of the board of directors of Coloplast A/S and the pharmaceutical company H. Lundbeck A/S. Lars Rasmussen is also a member of the board of directors of the medtech company Demant A/S and holds further management level posts in Germination af 2008 ApS, ADO Holding af 26.02.2004 and a subsidiary of the latter.Britt Meelby Jensen (born 1973) has extensive experience in the life science industry from leading positions in Novo Nordisk A/S and as the former CEO of diagnostics company Dako A/S and biotech company Zealand Pharma A/S. Currently, Britt Meelby Jensen is the CEO of the medtech company Atos Medical AB and is member of the Board of Directors of the Hempel Foundation.CONTACTS
Investor Relations
CFO Michael Højgaard, / +45 4030 4349
Morten Huse Eikrem-Jeppesen, / +45 5385 0770
AttachmentCompany Announcement_no. 18 2019_20

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.